The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for RFK Jr pushes for FDA approval of BPC 157 peptide Eric Topol, MD posted on the topic LinkedIn The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and BPC 157 erectile dysfunction study: what the current evidence actually shows BPC 157: Experimental Peptide Creates Risk for Athletes